Wordt geladen...
Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials
Background: Revefenacin, a novel, lung-selective, long-acting muscarinic antagonist, has been developed for nebulized therapy for chronic obstructive pulmonary disease (COPD). We present the results of replicate Phase III efficacy and safety studies of revefenacin in patients with moderate to very s...
Bewaard in:
| Gepubliceerd in: | Chronic Obstr Pulm Dis |
|---|---|
| Hoofdauteurs: | , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
COPD Foundation Inc
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6596436/ https://ncbi.nlm.nih.gov/pubmed/30974049 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15326/jcopdf.6.2.2018.0152 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|